Management strategy for adverse events of immune checkpoint inhibitors / 中国肿瘤临床

ABSTRACT

Currently, immune checkpoint inhibitors (ICPIs) are the most compelling approach in cancer therapy, which expanded the boundary of treatment of cancer to immune-based therapy. Compared to traditional chemotherapy, immunotherapy significantly pro-longs survival while conferring fewer side effects. Because of the new mechanism of the ICPIs with good clinical efficacy, they have been approved for sale in a short time. However, the mechanism of immune-related adverse events have yet fully understood for a standardized management strategy. With further development of immunotherapy and possible combination therapy, adverse events of ICPIs gain more attention. Here, we focuses on the reported adverse events and the treatment experience to provide theoretical ba-sis for their treatment.